Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the
tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and estramustine
with thalidomide in treating patients who have prostate cancer previously treated with
hormone therapy.